Lurtotecan Explained

Lurtotecan is a semi-synthetic analog of camptothecin with antineoplastic activity. Liposomal lurtotecan was in clinical trials as a treatment for topotecan-resistant ovarian cancer,^[1] but was discontinued.^[2]

Synthesis

• Heck reaction
• Mitsunobu reaction
• Potassium osmate
• Sharpless asymmetric dihydroxylation
• Swern oxidation

References

1. Seiden . MV . Muggia . F . Astrow . A . Matulonis . U . Campos . S . Roche . M . Sivret . J . Rusk . J . Barrett . E . A Phase II Study of Liposomal Lurtotecan (OSI-211) in Patients with Topotecan Resistant Ovarian Cancer . Gynecologic Oncology . April 2004 . 93 . 1 . 229–32 . 10.1016/j.ygyno.2003.12.037 . 15047241 .
2. Web site: Liposomal lurtotecan (OSI 211) on AdisInsight. Adis Insight. Springer International Publishing AG. 15 July 2016.